Schroeder Theodore R
SEC-identified person · CIK 1378690 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Phathom Pharmaceuticals, Inc. PHAT | Director | filed 2025 - 2026 |
| Cidara Therapeutics, Inc. CDTX | Director | filed 2015 - 2026 |
| Nabriva Therapeutics plc NBRV | Director · Chief Executive Officer) | filed 2018 - 2023 |
| Otonomy, Inc. OTIC | Director | filed 2015 - 2022 |
| Collegium Pharmaceutical, INC COLL | Director | filed 2016 - 2020 |
| Hyperion Therapeutics INC HPTX | Director | filed 2014 - 2015 |
| Cadence Pharmaceuticals INC CADX | Director · President, CEO | filed 2006 - 2014 |
| Trius Therapeutics Inc TSRX | Director | filed 2010 - 2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.